Carfilzomib (Synonyms: 卡非佐米; PR-171)

目录号: HY-10455 纯度: 99.95%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Carfilzomib (PR-171) 是不可逆的蛋白酶体 (proteasome) 抑制剂，其在ANBL-6和RPMI 8226细胞中的 IC₅₀ 为5 nM。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Carfilzomib Chemical Structure

CAS No. : 868540-17-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
5 mg	￥640	In-stock
10 mg	￥1020	In-stock
25 mg	￥1888	In-stock
50 mg	￥2850	In-stock
100 mg	￥4500	In-stock
200 mg	现货	询价
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Carfilzomib:

Carfilzomib-d₈ In-stock
Carfilzomib (Standard) 询价

MCE 顾客使用本产品发表的 38 篇科研文献

Carfilzomib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with an IC₅₀ of 5 nM in ANBL-6 and RPMI 8226 cells.

IC₅₀ & Target

IC50: 5 nM (Proteasome)

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A-431	IC₅₀	23.8 nM Compound: Carfilzomib	Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
A549	IC₅₀	43.3 nM Compound: Carfilzomib	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 30639896]
CCRF-CEM	IC₅₀	6.1 nM Compound: Carfilzomib	Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
HCT-116	IC₅₀	19.3 nM Compound: Carfilzomib	Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
HCT-116	IC₅₀	9.6 nM Compound: Carfilzomib	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 30639896]
LP-1	IC₅₀	22.7 nM Compound: Carfilzomib	Antiproliferative activity against human LP-1 cells after 72 hrs by MTS assay Antiproliferative activity against human LP-1 cells after 72 hrs by MTS assay	[PMID: 30639896]
MCF7	IC₅₀	0.0041 μM Compound: Cfz	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30165344]
MDA-MB-231	IC₅₀	0.0044 μM Compound: Cfz	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 30165344]
MES-SA	IC₅₀	18 nM Compound: 2	Cytotoxicity against human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 19348473]
MES-SA	IC₅₀	413 nM Compound: 2	Cytotoxicity against multidrug resistance transporter expressing doxorubicin resistant human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against multidrug resistance transporter expressing doxorubicin resistant human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay	[PMID: 19348473]
MGC-803	IC₅₀	934 nM Compound: Carfilzomib	Antiproliferative activity against human MGC803 cells after 72 hrs by MTS assay Antiproliferative activity against human MGC803 cells after 72 hrs by MTS assay	[PMID: 30639896]
MM1.S	IC₅₀	< 1 nM Compound: 2	Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay	[PMID: 30611983]
MM1.S	IC₅₀	1.5 nM Compound: Carfilzomib	Cytotoxicity against human MM1S cells measured after 72 hrs by MTS assay Cytotoxicity against human MM1S cells measured after 72 hrs by MTS assay	[PMID: 28027531]
MM1.S	IC₅₀	1.5 nM Compound: Carfilzomib	Antiproliferative activity against human MM1S cells measured after 72 hrs by MTS assay Antiproliferative activity against human MM1S cells measured after 72 hrs by MTS assay	[PMID: 27765408]
MM1.S	IC₅₀	14.35 nM Compound: Carfilzomib	Antiproliferative activity against human MM1.S cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MM1.S cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33223460]
MM1.S	IC₅₀	2.3 nM Compound: Carfilzomib	Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay	[PMID: 30639896]
MOLT-4	IC₅₀	5.1 nM Compound: 2	Inhibition of chymotrypsin-like activity of 20S proteasome in human MOLT4 cells after 1 hr by CellTiter-Glo luminescent assay Inhibition of chymotrypsin-like activity of 20S proteasome in human MOLT4 cells after 1 hr by CellTiter-Glo luminescent assay	[PMID: 19348473]
NCI-H23	IC₅₀	0.018 μM Compound: Cfz	Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H727	IC₅₀	0.6102 μM Compound: Cfz	Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
NCI-H929	IC₅₀	116.1 nM Compound: Carfilzomib	Antiproliferative activity against human NCI-H929 cells after 72 hrs by MTS assay Antiproliferative activity against human NCI-H929 cells after 72 hrs by MTS assay	[PMID: 30639896]
NCI-H929	IC₅₀	13.9 nM Compound: Carfilzomib	Antiproliferative activity against human NCI-H929 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H929 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33223460]
NCI-H929	IC₅₀	21.32 nM Compound: Carfilzomib	Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay Cytotoxic activity against human NCI-H929 cells after 72 hrs by MTS assay	[PMID: 24767818]
PC-3	IC₅₀	23.9 nM Compound: Carfilzomib	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 30639896]
RKO	IC₅₀	27.1 nM Compound: Carfilzomib	Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human RKO cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
RPMI-8226	IC₅₀	0.0067 μM Compound: Cfz	Cytotoxicity against human RPMI8226 cells after 48 hrs by MTT assay Cytotoxicity against human RPMI8226 cells after 48 hrs by MTT assay	[PMID: 30165344]
RPMI-8226	IC₅₀	0.007 μM Compound: Cfz	Cytotoxicity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay Cytotoxicity against human RPMI8226 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay	[PMID: 30964987]
RPMI-8226	IC₅₀	13.19 nM Compound: Carfilzomib	Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay Cytotoxic activity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 24767818]
RPMI-8226	IC₅₀	13.2 nM Compound: Carfilzomib	Cytotoxicity against human RPMI8226 cells measured after 72 hrs by MTS assay Cytotoxicity against human RPMI8226 cells measured after 72 hrs by MTS assay	[PMID: 28027531]
RPMI-8226	IC₅₀	13.2 nM Compound: Carfilzomib	Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by MTS assay Antiproliferative activity against human RPMI8226 cells measured after 72 hrs by MTS assay	[PMID: 27765408]
RPMI-8226	IC₅₀	14.1 nM Compound: Carfilzomib	Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human RPMI-8226 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33223460]
RPMI-8226	IC₅₀	2 nM Compound: 2	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 30611983]
RPMI-8226	IC₅₀	2.1 nM Compound: Carfilzomib	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay	[PMID: 30639896]
RPMI-8226	IC₅₀	39.1 nM Compound: Kyprolis(R)	Cytotoxicity against human RPMI8226 cells assessed as cell viability measured after 72 hrs by celltiter96 aqueous cell proliferation assay Cytotoxicity against human RPMI8226 cells assessed as cell viability measured after 72 hrs by celltiter96 aqueous cell proliferation assay	[PMID: 31383629]
TOV21G	IC₅₀	23.8 nM Compound: Carfilzomib	Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay Antiproliferative activity against human TOV21G cells after 72 hrs by oxyluciferin luminescence assay	[PMID: 26231162]
U-266	IC₅₀	35.7 nM Compound: Kyprolis(R)	Cytotoxicity against human U266B1 cells assessed as cell viability measured after 72 hrs by celltiter96 aqueous cell proliferation assay Cytotoxicity against human U266B1 cells assessed as cell viability measured after 72 hrs by celltiter96 aqueous cell proliferation assay	[PMID: 31383629]

体外研究
(In Vitro)

Carfilzomib 在体外显示出对 β5 亚基中 ChT-L 活性的优先抑制效力，在 10 nM 和更高剂量时抑制超过 80%，在剂量高达 100 nM 时对 PGPH 和 TL 活性影响很小或没有影响。Carfilzomib 降低 ANBL-6、RPMI 8226 细胞、U266 和 KAS-6/1 细胞的活力，IC₅₀ 小于 5 nM。Carfilzomib 克服了 Dex 耐药性，因为 MM1.R 细胞的 IC₅₀ 为 15.2 nM，低于亲本 MM1.S 细胞的 29.3 nM 值^[1]。
与 carfilzomib 和 HDACI 共同处理导致在各种套细胞淋巴瘤细胞系和原代套细胞淋巴瘤细胞中协同诱导细胞死亡。在 HF-4B 和 Granta 细胞中，Carfilzomib 或 ONX0912 与伏立诺他联合处理可显著增加半胱天冬酶活化、PARP 裂解、JNK 活化、MnSOD2 诱导和 DNA 损伤^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Carfilzomib (2.0 mg/kg，iv) 与 70 mg/kg Vorinostat 联用几乎消除了 Granta-luciferace 细胞异种移植模型中的肿瘤生长。与使用单一药物或毒性极小的对照组相比，联合处理可显著减少生物发光^[2]。

Carfilzomib 在大鼠体内表现出高血浆清除率 (195-319 mL/min•kg)、短的终末半衰期 (5-20 min) 和快速而广泛的组织分布。Carfilzomib 的暴露量 (C_max 和曲线下面积) 随剂量增加而增加。高清除率主要通过肽酶裂解和环氧水解的肝外代谢介导，尿液和胆汁中分别占总剂量的约 26%和 31%。尽管全身清除率高，但在血液和多种组织中均观察到强的蛋白酶体抑制^[2]。
Carfilzomib 可用于动物建模，构建心脏毒性和高血压模型。

1. 心脏毒性模型^[3]

致病原理

Carfilzomib 可抑制 AMPKα 介导的自噬和 PI3K/Akt/eNOS 轴，随后导致心肌细胞损伤和细胞凋亡，导致心脏毒性。

具体造模方法

小鼠：C57BL/6 • 雄性 • 12-14 周龄
给药：8 mg/kg • 腹腔注射 • 每 2 天一次，共 7 天

造模成功指标

分子变化：降低了 AMPKα、Raptor、LC3-II、PI3K、Akt 和 eNOS 的磷酸化。

血流动力学：左心室 FS% 降低，即收缩功能减弱。

拮抗产品 Metformin (HY-B0627)

2. 高血压模型^[4]

致病原理

Carfilzomib 诱导的 AMPKα 去磷酸化导致肾脏集合管离子通道稳态失调，从而水离子重吸收失调导致心脏前负荷增加来诱发高血压。

具体造模方法

小鼠：C57BL/6 • 雄性 • 12-14 周龄
给药：8 mg/kg • 腹腔注射 • 每 2 天一次，共 7 天

造模成功指标

分子变化：诱导型一氧化氮合酶 (iNOS) 和微管相关蛋白 1A/1B 轻链 3B (LC3-B) 表达增加，AMPKα 磷酸化降低。集合管离子通道上皮 Na⁺ 通道 (ENaC)、Na⁺/K⁺/ATPase 和尿素转运蛋白 1 (UTA-1) mRNA 水平升高。

行为观测：小鼠肾周脂肪组织出现炎症。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

719.91

同用名

卡非佐米; PR-171

Formula

C₄₀H₅₇N₅O₇

CAS 号

868540-17-4

性状

固体

颜色

White to off-white

中文名称

卡非佐米

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

溶解性数据

细胞实验：

DMSO 中的溶解度 : 125 mg/mL (173.63 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3891 mL	6.9453 mL	13.8906 mL
5 mM	0.2778 mL	1.3891 mL	2.7781 mL
10 mM	0.1389 mL	0.6945 mL	1.3891 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (3.47 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.47 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案三

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.5 mg/mL (3.47 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*该产品在溶液状态不稳定，建议您现用现配，即刻使用。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.96%

选择批次：

Data Sheet (681 KB) SDS (393 KB)

COA (292 KB) RP-HPLC (335 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Kawada T, Iwai K. In vivo and in vitro metabolism of dihydrocapsaicin, a pungent principle of hot pepper [Capsicum annuum], in rats[J]. Agricultural and Biological Chemistry (Japan), 1985, 49(2).

[2]. Yang J, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011 Oct;39(10):1873-82. [Content Brief]

[3]. Efentakis P, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019 Feb 14;133(7):710-723. [Content Brief]

[4]. Panagiotis Efentakis, et al. Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α. Blood, Volume 136, Supplement 1, 2020, Pages 34-35, ISSN 0006-4971.

Cell Assay ^[1]	WST-1 is used to determine the effects of proteasome inhibitors on cell proliferation according to the manufacturer's protocol. The inhibition of proliferation is calculated in relation to parallel control cells that receive vehicle alone and tabulated in KaleidaGraph 3.0.1 or Excel 2000. A linear spline function is used to interpolate the median inhibitory concentration (IC₅₀) using XLfit 4 software. The degree of resistance (DOR) is calculated using the formula: DOR=IC₅₀(resistant cells)/IC₅₀(sensitive cells). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Animal studies are performed utilizing Beige-nude-XID mice. 10×10⁶ Granta514 cells are pelleted, washed twice with 1X PBS, injected subcutaneously into the right flank. Once the tumors are visible, 5 to 6 mice are treated with carfilzomib±vorinostat and progress of tumor growth or regression is monitored. Stock vorinostat and carfilzomib is dissolved in DMSO and 10% sulfobutylether betacyclodextrin in 10 mM citrate buffer pH respectively. They are stored in −80°C in small aliquots and diluted before injection. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Kawada T, Iwai K. In vivo and in vitro metabolism of dihydrocapsaicin, a pungent principle of hot pepper [Capsicum annuum], in rats[J]. Agricultural and Biological Chemistry (Japan), 1985, 49(2). [2]. Yang J, et al. Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011 Oct;39(10):1873-82. [Content Brief] [3]. Efentakis P, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019 Feb 14;133(7):710-723. [Content Brief] [4]. Panagiotis Efentakis, et al. Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α. Blood, Volume 136, Supplement 1, 2020, Pages 34-35, ISSN 0006-4971.

Carfilzomib 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.3891 mL	6.9453 mL	13.8906 mL	34.7266 mL
	5 mM	0.2778 mL	1.3891 mL	2.7781 mL	6.9453 mL
	10 mM	0.1389 mL	0.6945 mL	1.3891 mL	3.4727 mL
	15 mM	0.0926 mL	0.4630 mL	0.9260 mL	2.3151 mL
	20 mM	0.0695 mL	0.3473 mL	0.6945 mL	1.7363 mL
	25 mM	0.0556 mL	0.2778 mL	0.5556 mL	1.3891 mL
	30 mM	0.0463 mL	0.2315 mL	0.4630 mL	1.1576 mL
	40 mM	0.0347 mL	0.1736 mL	0.3473 mL	0.8682 mL
	50 mM	0.0278 mL	0.1389 mL	0.2778 mL	0.6945 mL
	60 mM	0.0232 mL	0.1158 mL	0.2315 mL	0.5788 mL
	80 mM	0.0174 mL	0.0868 mL	0.1736 mL	0.4341 mL
	100 mM	0.0139 mL	0.0695 mL	0.1389 mL	0.3473 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Carfilzomib868540-17-4PR-171卡非佐米PR171PR 171ProteasomeAutophagyApoptosisInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Carfilzomib (Synonyms: 卡非佐米; PR-171)

Customer Review

Other Forms of Carfilzomib:

MCE 顾客使用本产品发表的 38 篇科研文献

Carfilzomib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Carfilzomib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Carfilzomib (Synonyms: 卡非佐米; PR-171)

Customer Review

Other Forms of Carfilzomib:

Carfilzomib 相关抗体

MCE 顾客使用本产品发表的 38 篇科研文献

Carfilzomib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Carfilzomib 相关抗体:

摩尔计算器

稀释计算器

Carfilzomib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z